Clinical trials: Uncontrolled Asthma
Asthma
Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma
The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a…
- Trial name
- NCT01181895
- Testing
- Vilanterol, Salmeterol Inhalation Powder
- Where
- 34 sites in United States, Germany and 3 more
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Asthma, Gastroesophageal Reflux
Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma
This study will evaluate the effect of CYP2C19 and ABCB1 genes on pharmacokinetics of lansoprazole in children with mild gastroesophageal reflux (GER) and uncontrolled asthma.
- Trial name
- GenARA (NCT03015610)
- Testing
- commercially available lansoprazole
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Jason Lang, M.D., M.P.H.
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00603746
- Testing
- GW685698X
- Where
- 154 sites in United States, Australia and 14 more
- Volunteers
- 627 people
- Sponsor
- GlaxoSmithKline
Asthma
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
This study aimed to determine the efficacy and safety of QAW039 and QAW039 450 mg compared to placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016) in the…
- Trial name
- NCT02563067
- Testing
- QAW039
- Where
- 163 sites in United States, Argentina and 17 more
- Volunteers
- 877 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Study to Test if TEV-48574 is Effective in Relieving Asthma
The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult participants with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids…
- Trial name
- NCT04545385
- Testing
- TEV-48574
- Where
- 97 sites in United States, Bulgaria and 3 more
- Volunteers
- 65 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy, safety, and tolerability of lebrikizumab in adolescent participants with asthma whose disease remains uncontrolled…
- Trial name
- NCT01875003
- Testing
- Lebrikizumab, Standard of Care
- Where
- 81 sites in United States, Argentina and 19 more
- Volunteers
- 346 people
- Sponsor
- Hoffmann-La Roche
Asthma
Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma
The goal of asthma treatment is to achieve and maintain asthma control and to reduce the future risk of exacerbations. Inhaled corticosteroids (ICS) are considered as the most effective anti- inflammatory treatment for all…
- Trial name
- NCT03248128
- Testing
- FF/VI via ELLIPTA DPI, FF via ELLIPTA DPI
- Where
- 183 sites in United States, Argentina and 14 more
- Volunteers
- 906 people
- Sponsor
- GlaxoSmithKline
Asthma, Bronchial Diseases
Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.
- Conditions
- Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive
- Trial name
- CASCADE (NCT03688074)
- Testing
- Tezepelumab
- Where
- 28 sites in United States, Canada and 3 more
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
Asthma
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium…
- Trial name
- ARGON (NCT03158311)
- Testing
- QVM149, Salmeterol/fluticasone plus tiotropium
- Where
- 163 sites in Argentina, Chile and 18 more
- Volunteers
- 1,426 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00603278
- Testing
- GW685698X
- Where
- 155 sites in United States, Canada and 11 more
- Volunteers
- 622 people
- Sponsor
- GlaxoSmithKline
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma
The primary objective of the study is to evaluate the effect of multiple-dose subcutaneous administrations of MEDI-563 on adults with uncontrolled asthma.
- Trial name
- NCT01238861
- Testing
- Benralizumab 2 mg, Benralizumab 20 mg, Benralizumab 100 mg
- Where
- 74 sites in United States, Argentina and 8 more
- Volunteers
- 964 people
- Sponsor
- MedImmune LLC
Asthma
Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids
This study will compare two treatment strategies (doubling the dose of inhaled steroids or adding a long acting beta2 agonist to the inhaled steroid at the same dose) in children not controlled by inhaled steroid alone at medium…
- Trial name
- NCT00353873
- Testing
- Fluticasone propionate, Fluticasone propionate/salmeterol
- Where
- 65 sites in Belgium, Denmark and 10 more
- Volunteers
- 506 people
- Sponsor
- GlaxoSmithKline
Asthma
Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011)
The purpose of this study is to evaluate the effect of MK-1029 on lung function in the treatment of adults who have persistent asthma that is uncontrolled with the use of montelukast (ML).
- Trial name
- NCT01624974
- Testing
- MK-1029, Montelukast (ML)
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Asthma
A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications
The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate (50, 100, 200, and 400mcg) delivered as Fluticasone Spiromax® Inhalation Powder (Fp…
- Trial name
- NCT01576718
- Testing
- Fp MDPI, Flovent Diskus, albuterol/salbutamol
- Where
- 300 sites in United States, Australia and 17 more
- Volunteers
- 889 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Severe Asthma
Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma
This is an open-label, single arm study designed to evaluate the safety of tezepelumab administered subcutaneously every 4 weeks in Japanese adult and adolescent subjects with inadequately controlled severe asthma.
- Trial name
- NOZOMI (NCT04048343)
- Testing
- Biological: Experimental: Tezepelumab
- Where
- 5 sites in Japan
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Asthma
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.
The purpose of this study is to investigate the effect of benralizumab on the rate of asthma exacerbations, patient reported quality of life and lung function during the 24-week treatment in patients with uncontrolled, severe…
- Trial name
- ANDHI (NCT03170271)
- Testing
- Benralizumab (Medi-563)
- Where
- 213 sites in United States, Austria and 12 more
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
Asthma
One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids
The primary objective of this study is to evaluate efficacy of AZD1981 in uncontrolled asthmatic patients on maintenance inhaled glucocorticosteroids.
- Trial name
- OLIVE (NCT00758589)
- Testing
- AZD1981
- Where
- 21 sites in Argentina, Brazil and 2 more
- Volunteers
- 368 people
- Sponsor
- AstraZeneca
Asthma
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
The purpose of this study is to determine the efficacy and safety of multiple CSJ117 doses (0.5; 1; 2; 4 and 8 mg) inhaled once daily compared with placebo, when added to standard-of-care (SoC) asthma therapy in adult patients…
- Trial name
- NCT04410523
- Testing
- CSJ117
- Where
- 113 sites in United States, Argentina and 13 more
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
- Trial name
- NCT00603382
- Testing
- GW685698X
- Where
- 149 sites in United States, Bulgaria and 12 more
- Volunteers
- 599 people
- Sponsor
- GlaxoSmithKline